Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Sells $877,500.00 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) insider John Tilton sold 30,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.25, for a total value of $877,500.00. Following the sale, the insider now owns 30,000 shares in the company, valued at approximately $877,500. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/11/02/biohaven-pharmaceutical-holding-co-ltd-bhvn-insider-sells-877500-00-in-stock.html.

Large investors have recently made changes to their positions in the company. Deschutes Portfolio Strategy LLC bought a new position in shares of Biohaven Pharmaceutical Holding Co during the third quarter valued at about $374,000. American Century Companies Inc. bought a new position in shares of Biohaven Pharmaceutical Holding Co during the third quarter valued at about $1,375,000. State of Wisconsin Investment Board bought a new position in shares of Biohaven Pharmaceutical Holding Co during the third quarter valued at about $262,000. Emerald Mutual Fund Advisers Trust bought a new position in shares of Biohaven Pharmaceutical Holding Co during the third quarter valued at about $7,483,000. Finally, Emerald Advisers Inc. PA bought a new position in shares of Biohaven Pharmaceutical Holding Co during the third quarter valued at about $9,096,000.

A number of brokerages recently weighed in on BHVN. BidaskClub lowered Biohaven Pharmaceutical Holding Co from a “hold” rating to a “sell” rating in a research report on Friday, October 27th. Zacks Investment Research upgraded Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. William Blair restated an “outperform” rating on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, October 3rd. Morgan Stanley restated an “overweight” rating and set a $38.00 price objective (down previously from $47.00) on shares of Biohaven Pharmaceutical Holding Co in a research report on Tuesday, October 3rd. Finally, Needham & Company LLC reduced their price objective on Biohaven Pharmaceutical Holding Co from $43.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $40.80.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

What are top analysts saying about Biohaven Pharmaceutical Holding Co Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Biohaven Pharmaceutical Holding Co Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit